Prot #NLG-0301: An Open-label, Randomized Phase IIb/III Active Control Study of Second-line HyperAcute®-Lung (tergenpumatucel-L) Immunotherapy versus Docetaxel in Progressive or Relapsed Non-Small Cell Lung Cancer

Project: Research project

Project Details

StatusFinished
Effective start/end date11/22/13 → 11/22/16

Funding

  • NewLink Genetics Corporation (Prot #NLG-0301)